|Series C, 9/2009 |
Ottawa Regional Cancer Foundation
|Series D, 10/2010 ||$8.6M|
|Venture Round, 8/2011 ||$8.6M|
|Seed, 10/2011 ||$1.75M|
|Private Equity, 5/2013 ||$21.6M|
Jennerex is a clinical-stage biopharmaceutical company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. The companyâ€™s lead product JX-594, currently in an international Phase 2 trial for primary liver cancer and colorectal cancer, demonstrated promising Phase 1 efficacy and safety results in patients with a diverse array of common cancers.